KRAS, KRAS proto-oncogene, GTPase, 3845

N. diseases: 1213; N. variants: 54
Disease: HER2 gene amplification ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1512127
Disease: HER2 gene amplification
HER2 gene amplification 		0.100 AlteredExpression disease BEFREE We found that HER2 amplification is rare and poorly associated to IHC overexpression in extracolonic and extragastric GIT cancers; however in KRAS wild type colorectal cancers, which fail conventional treatment, HER2 IHC may be useful and should be considered. 31221175 2019
CUI: C1512127
Disease: HER2 gene amplification
HER2 gene amplification 		0.100 Biomarker disease BEFREE No relationship was found between HER2 amplification and KRAS status (p = 0.052). 31729406 2019
CUI: C1512127
Disease: HER2 gene amplification
HER2 gene amplification 		0.100 GeneticVariation disease BEFREE Except for the detection of ERBB2 amplification and KRAS mutation in two patients, no other classic lung cancer driver mutations were detected. 31659278 2019
CUI: C1512127
Disease: HER2 gene amplification
HER2 gene amplification 		0.100 GeneticVariation disease BEFREE CGS successfully detected alterations in 415 genes including KRAS codon 12/13 mutation and HER2 amplification. 28235632 2017
CUI: C1512127
Disease: HER2 gene amplification
HER2 gene amplification 		0.100 GeneticVariation disease BEFREE KRAS mutation and HER2 amplification were detected in 30% and 7% of cases, respectively, without prognostic implications. 28333239 2017
CUI: C1512127
Disease: HER2 gene amplification
HER2 gene amplification 		0.100 GeneticVariation disease BEFREE We screened for three molecular targets: HER2 amplification; KRAS wild-type; and mutations in DNA damage repair pathways (BRCA1, BRCA2, PALB2, ATM). 25896973 2015
CUI: C1512127
Disease: HER2 gene amplification
HER2 gene amplification 		0.100 GeneticVariation disease BEFREE Regions of disparate ERBB2-amplification status were sequenced independently for two mucinous carcinoma (MC) cases, previously established as showing ERBB2 amplification/overexpression heterogeneity, to assess the hypothesis of subclonal populations containing either KRAS mutation or ERBB2 amplification independently or simultaneously. 25986173 2015
CUI: C1512127
Disease: HER2 gene amplification
HER2 gene amplification 		0.100 AlteredExpression disease BEFREE HER2 protein overexpression and HER2 amplification were found more frequently in eyelid SCs than in other eyelid tumors.All SCs harbored wild type KRAS genes. 25468813 2015
CUI: C1512127
Disease: HER2 gene amplification
HER2 gene amplification 		0.100 GeneticVariation disease BEFREE KRAS mutations were seen in 31/71 (43.6%) MCs and 26/33 (78.8%) MBOTs, and were near mutually exclusive of HER2 amplification. 22899400 2013
CUI: C1512127
Disease: HER2 gene amplification
HER2 gene amplification 		0.100 GeneticVariation disease BEFREE EGFR and HER2 gene amplification was observed in 5.3% and 26.3%, respectively, of KRAS and BRAF wild type colorectal cancer patients. 20563851 2011
CUI: C1512127
Disease: HER2 gene amplification
HER2 gene amplification 		0.100 GeneticVariation disease BEFREE To further determine the genetic and molecular characteristics of tumors carrying EGFR gene mutations, we investigated the EGFR gene status in lung adenocarcinomas and evaluated its association with specific characteristics of the patients and tumors, such as mutations at KRAS and p53, EGFR and ErbB2 gene amplification, levels of EGFR and HER2 proteins, and levels of downstream effectors of EGFR, such as phospho-extracellular signal-regulated kinase and phospho-S6 proteins. 16467080 2006
CUI: C1512127
Disease: HER2 gene amplification
HER2 gene amplification 		0.100 AlteredExpression disease BEFREE The aim of this study was to detect activated c-K-ras by gene point mutation and to find c-erbB-2 gene amplification with p185 expression in association with the c-K-ras gene product p21 in the human endometrium. 11553860 2001